Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05206097

Determinants of Daily Physical Activity Level in Patients With Cystic Fibrosis - Pilot Study Protocol

The aim of the study is to analyze the determinants (barriers and facilitators) of the daily physical activity level in a population of patients with cystic fibrosis. A population of patients will be included in order to realize an assessment of their daily physical activity level over an entire week. A specific questionnaire, designed from 3 different questionnaires, will be associated to the physical activity evaluation and will allow to asses psycho-social and environmental factors.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU DE BORDEAUX Hôpital Haut-Lévêque - CRCM Adulte, Bordeaux, France

Loading trial locations.

About this study

Physical activity (PA) is a major component of the management of patients with cystic fibrosis (CF). Regular PA is associated, in cystic fibrosis as in other pathologies, with health benefits and a greater life expectancy. However, the literature shows an absence of consensus for the daily PA level reached by CF patients, and also for the determinants of this PA level. It appears that CF patients tend to have a reduced PA level, compared to international guidelines. Some determinants have already been mentioned, like physical, psychological or organizational factors. But these factors have not been considered in a multifactorial way, by also considering social and environmental factors, and are rarely associated with objective PA level measurement or only reported in paediatric population. A better comprehension of these determinants of daily PA level represents an important issue for the optimization of interventions designed for the promotion of PA in cystic fibrosis.

For this study, a population of CF patients will realize an evaluation of their daily PA level based on accelerometry (by wearing a portable device over 7 days). During the PA assessment, patients will have a questionnaire to fill in, delivered with the sensor. The objective assessment of PA level will be analyzed with regard to various parameters from different dimensions: individual, clinical, psycho-social and environmental. Individual and clinical parameters will be collected from patients' data routinely assessed for the management of patients. Psycho-social and environmental parameters will be assessed with a specific questionnaire, specifically designed from 3 different questionnaires.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of cystic fibrosis confirmed by the identification of genetic mutation and/or positive sweat test
  • regular follow-up in CF centers ;
  • age higher than 6 years old
  • stable clinical status, away from exacerbation period or antibiotic treatment.

Exclusion criteria

  • transplant patient or patient waiting for a transplant
  • inability to fill in the questionnaire or to complete the planned evaluations
  • ongoing participation in another research protocol (interventional study)
  • refusal to participate in the study
  • patient under legal protection.

Treatment and study plan

Accelerometer

Device

For the following study, each patient will be asked to wear a portable device over a 7-day period. The accelerometer will be previously set up according to anthropometric data of the patient and scheduled to automatically start and stop accelerations registration. The patient will be asked to wear the sensor as frequently as possible, with the exception of sleep period and during aquatic activities. A diary will be delivered to the patient in order to notify any problem/issue observed during the evaluation week (for example forgetting to wear the sensor). The accelerometry assessment will be associated to a questionnaire. Each patient will have to fill in it during the evaluation week. The questionnaire is composed of various questions from three different questionnaires: Ricci & Gagnon for subjective evaluation of PA level, CFQ-14+ for the evaluation of quality of life specifically in CF and EQ-5D for a more generic evaluation of quality of life.

Primary outcomes

  1. Physical Activity Time

    Time frame: Week 1

    mean value of moderate to vigorous Physical Activity (MVPA) time (min/day), from an accelerometry evaluation over an entire week

Secondary outcomes

  1. Daily Physical Activity level

    Time frame: Week 1

    Daily Physical Activity level, from the accelerometry evaluation compared to international PA guidelines

  2. Duration of Physical Activity

    Time frame: Week 1

    Duration of Physical Activity performed by patients

  3. Frequency of Physical Activity

    Time frame: Week 1

    Frequency of Physical Activity performed by patients

  4. Type of Physical Activity

    Time frame: Week 1

    Type of Physical Activity performed by patients

  5. Sedentarity time

    Time frame: Week 1

    Sedentarity time, from the accelerometry evaluation.

Sponsors and collaborators

Lead sponsor

University Hospital, Limoges

Other

Registry information

Official study title

Determinants of Daily Physical Activity Level in Patients With Cystic Fibrosis - Pilot Study. Protocol

Acronym: APM

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Jan 25, 2022
Registry last updated
Dec 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.